AWM
SLNO

AE Wealth Management’s Soleno Therapeutics SLNO Stock Holding History

AE Wealth Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-709
Closed -$25K – 1334
2020
Q1 		$25K Buy
+709
New +$30.2K ﹤0.01% 1086

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AE Wealth Management's SLNO Position: Q2 2020 in Review

AE Wealth Management sold out of Soleno Therapeutics (SLNO) in Q2 2020, closing a stake of 709 shares — an estimated $25K sold.

AE Wealth Management first reported a position in SLNO in Q1 2020 and held it in 1 quarter. The position peaked at $25K in Q1 2020. 64 funds tracked by Wall St. Rank hold SLNO as of Q2 2020.

  • AE Wealth Management reported no remaining Soleno Therapeutics position as of Q2 2020 after selling out during the quarter.
  • AE Wealth Management sold 709 Soleno Therapeutics shares in Q2 2020, an estimated $25K.
  • AE Wealth Management first reported a position in Soleno Therapeutics in Q1 2020 and held it in 1 quarter.
  • AE Wealth Management's Soleno Therapeutics position peaked at $25K in Q1 2020.
  • 64 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2020.

Based on AE Wealth Management's 13F filing for Q2 2020, filed 5 Aug 2020.